Last reviewed · How we verify
Vaccination of Melanoma Patients With Tyrosinase YMD and gp100 IMD-Javelin Fusion Peptides/HSP70 Complexes: A Trial Comparing the Immunogenicity of Three Doses
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage III or stage IV melanoma.
Details
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Start date | 1999-06 |
| Completion | 2002-06 |
Conditions
- Melanoma (Skin)
Interventions
- OVA BiP peptide
- gp209-2M antigen
- recombinant 70-kD heat-shock protein
- tyrosinase peptide
Countries
United States